

Press release

Stockholm | August 2024

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman & Partners hires Camilla Oxhamre Cruse as Portfolio Manager – biotech and pharma. She will have a particular focus on companies within pharmaceutical development. Camilla joins Rhenman & Partners' investment team of four people, all based in their Stockholm office. Camilla has a master's degree in biochemistry from Lund University (Lund) and obtained a doctorate in medicine from Karolinska Institutet (Stockholm). In addition, she has an MBA from Hawaii Pacific University in the US and has studied at the École Nationale Supérieure de Chimie de Montpellier in France. Camilla has spent most of her career in the financial industry in a variety of advisory and analyst roles with a focus on the healthcare sector. This includes roles at Newton Investment Management (London), William Blair Investment Management (Chicago and London) and Carnegie Investment Bank (Stockholm). Camilla is ESG certified via PRI Academy.

"We are very pleased that Camilla will become part of Rhenman & Partners. Camilla's long international background and broad expertise in the medical field combined with her experience in the financial markets will be a strong addition to our organization. Camilla will work closely with the entire investment team, focusing on the biotech and pharmaceutical sub-sectors where we continue to see great potential." - says Henrik Rhenman, co-founder and CIO at Rhenman & Partners.

"I look forward to joining Rhenman & Partners. It is a company that I have followed for a long time and that has impressed me with its in-depth fundamental analysis in the healthcare sector, integrity and skillful management which has led to a long track record of positive returns. I am really pleased to become part of the team and to be able to contribute with my many years of analytical experience of the global pharmaceutical sector." - says Camilla Oxhamre Cruse.

Camilla joins Rhenman & Partners at the beginning of September.



Camilla Oxhamre Cruse

Continued on next page.

For more information, please contact:

Karin Hjertén | Head of Communications, Rhenman & Partners Asset Management
Telephone: +46 (0)706521908 | Email: karin@rhepa.com

Rhenman & Partners Asset Management

Rhenman & Partners Asset Management AB (Rhepa) was founded in 2008 and is a Stockholm-based asset manager with a sole focus on the healthcare sector. Rhepa is responsible for the portfolio of a sector fund registered in Luxembourg. The fund is managed by FundRock Management Company S.A. who has commissioned Rhepa to manage the fund's portfolio. Rhepa's experienced investment team is supported by a scientific advisory board consisting of medical experts with a global network of researchers and specialists.

This is marketing material, the material is for informational purposes only and should not be considered as an offer or solicitation to sell or buy shares in the fund. Read the AIF fund's prospectus as well as the KIID (which can be ordered free of charge or downloaded at www.rhepa.com) before making any definitive investment decisions. Historical returns are no guarantee of future returns. Investments involve a risk. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back all the invested capital. FundRock Management Company S.A., Luxembourg has commissioned Rhenman & Partners Asset Management AB to manage the portfolio in a Luxembourg-registered sector fund. Rhenman & Partners is not authorized to give - and will not give - investment advice to investors. Investors and potential investors considering investing in the Fund should discuss this with a professional investment adviser.